Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children

被引:4
作者
Chen, Liyuan [1 ]
Liu, Fen [1 ]
Fang, Danna [1 ]
Li, Jianwei [1 ]
机构
[1] Guangdong Med Univ, Dept Neurol, Dongguan Childrens Hosp, Dongguan, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2023年 / 11卷
关键词
nusinersen; SMA; motor function; platelet; urinary protein; ANTISENSE OLIGONUCLEOTIDE; SHAM CONTROL;
D O I
10.3389/fped.2023.1294405
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction/aimsThe time span for the approval of nusinersen to treat SMA remains short. Most studies on the efficacy and safety of this drug within clinical trials, are lacking real-world research data. This study is based on real-world studies of SMA patients in children with type II and III SMA and is committed to objectively evaluating the effectiveness and safety of this drug.MethodsA retrospective analysis was conducted on the clinical data of 18 children with type II and III SMA from January 2022 to June 2023. The motor function assessment scale, SMN protein, platelet, liver and kidney function, and other laboratory indicators of all patients before and after treatment were collected for statistical analysis.ResultsAfter load dose treatment (after 64 days of treatment), compared with baseline, the Revised Upper Limb Module (RULM) of SMA patients showed significant improvement (improvement rate: 44%), confirming the short-term effectiveness of the drug. The increase in cerebrospinal fluid SMN protein was greater in patients with significant improvement in motor function than in patients without improvement in motor function. Compared with baseline, there was no significant increase in AST and ALT levels in SMA patients, indicating that the drug had almost no effect on the liver. After each treatment, thrombocytopenia and partial urinary protein positivity may occur, but it could recover before the next treatment. This indicates that nusinersen is potentially harmful to platelet and renal function, although the effect is weak and reversible.DiscussionNusinersen has shown good efficacy and overall safety, but platelets and urinary protein are still indicators that require long-term monitoring. The increase in cerebrospinal fluid SMN protein was greater in patients with significant improvement in motor function than in patients without improvement in motor function.
引用
收藏
页数:8
相关论文
共 28 条
[1]   Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study [J].
Acsadi, Gyula ;
Crawford, Thomas O. ;
Mueller-Felber, Wolfgang ;
Shieh, Perry B. ;
Richardson, Randal ;
Natarajan, Niranjana ;
Castro, Diana ;
Ramirez-Schrempp, Daniela ;
Gambino, Giulia ;
Sun, Peng ;
Farwell, Wildon .
MUSCLE & NERVE, 2021, 63 (05) :668-677
[2]   Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy [J].
Alves, Christiano R. R. ;
Zhang, Ren ;
Johnstone, Alec J. ;
Garner, Reid ;
Nwe, Pann H. ;
Siranosian, Jennifer J. ;
Swoboda, Kathryn J. .
NEUROLOGY, 2020, 94 (09) :E921-E931
[3]   Safety of antisense oligonucleotide and siRNA-based therapeutics [J].
Chi, Xuan ;
Gatti, Philip ;
Papoian, Thomas .
DRUG DISCOVERY TODAY, 2017, 22 (05) :823-833
[4]   Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy [J].
Chiriboga, Claudia A. ;
Swoboda, Kathryn J. ;
Darras, Basil T. ;
Iannaccone, Susan T. ;
Montes, Jacqueline ;
De Vivo, Darryl C. ;
Norris, Daniel A. ;
Bennett, C. Frank ;
Bishop, Kathie M. .
NEUROLOGY, 2016, 86 (10) :890-897
[5]   An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials [J].
Darras, Basil T. ;
Farrar, Michelle A. ;
Mercuri, Eugenio ;
Finker, Richard S. ;
Foster, Richard ;
Hughes, Steven G. ;
Bhan, Ishir ;
Farwell, Wildon ;
Gheuens, Sarah .
CNS DRUGS, 2019, 33 (09) :919-932
[6]   Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study [J].
De Vivo, Darryl C. ;
Bertini, Enrico ;
Swoboda, Kathryn J. ;
Hwu, Wuh-Liang ;
Crawford, Thomas O. ;
Finkel, Richard S. ;
Kirschner, Janbernd ;
Kuntz, Nancy L. ;
Parsons, Julie A. ;
Ryan, Monique M. ;
Butterfield, Russell J. ;
Topaloglu, Haluk ;
Ben-Omran, Tawfeg ;
Sansone, Valeria A. ;
Jong, Yuh-Jyh ;
Shu, Francy ;
Staropoli, John F. ;
Kerr, Douglas ;
Sandrock, Alfred W. ;
Stebbins, Christopher ;
Petrillo, Marco ;
Braley, Gabriel ;
Johnson, Kristina ;
Foster, Richard ;
Gheuens, Sarah ;
Bhan, Ishir ;
Reyna, Sandra P. ;
Fradette, Stephanie ;
Farwell, Wildon .
NEUROMUSCULAR DISORDERS, 2019, 29 (11) :842-856
[7]   Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy [J].
Feldkötter, M ;
Schwarzer, V ;
Wirth, R ;
Wienker, TF ;
Wirth, B .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 70 (02) :358-368
[8]   Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy [J].
Finkel, R. S. ;
Mercuri, E. ;
Darras, B. T. ;
Connolly, A. M. ;
Kuntz, N. L. ;
Kirschner, J. ;
Chiriboga, C. A. ;
Saito, K. ;
Servais, L. ;
Tizzano, E. ;
Topaloglu, H. ;
Tulinius, M. ;
Montes, J. ;
Glanzman, A. M. ;
Bishop, K. ;
Zhong, Z. J. ;
Gheuens, S. ;
Bennett, C. F. ;
Schneider, E. ;
Farwell, W. ;
De Vivo, D. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) :1723-1732
[9]   Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study [J].
Finkel, Richard S. ;
Chiriboga, Claudia A. ;
Vajsar, Jiri ;
Day, John W. ;
Montes, Jacqueline ;
De Vivo, Darryl C. ;
Yamashita, Mason ;
Rigo, Frank ;
Hung, Gene ;
Schneider, Eugene ;
Norris, Daniel A. ;
Xia, Shuting ;
Bennett, C. Frank ;
Bishop, Kathie M. .
LANCET, 2016, 388 (10063) :3017-3026
[10]   Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective [J].
Frazier, Kendall S. .
TOXICOLOGIC PATHOLOGY, 2015, 43 (01) :78-89